secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2025-08-25T23:59:59+00:00
Accession:  0001708599-25-000105
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA feedback supports registrational trial for SER-252 in advanced Parkinson's under 505(b)(2) NDA pathway
--------------------------------------------------------------------------------

- FDA Type B meeting written feedback supports advancing SER-252 (POZ-apomorphine) in registrational study.
- Plans to submit U.S. IND in Q4 2025; patient dosing in Australia expected to start in Q4 2025.
- U.S. enrollment expected to begin in Q1 2026 after IND clearance.
- SER-252-1b study is randomized, double-blind, placebo-controlled Phase 1b with up to 88 patients.
- CEO highlights capital-efficient 505(b)(2) pathway; platform may apply to other POZ-enabled small molecules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000105/0001708599-25-000105-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000105/ser-20250825.htm
  HTML page:      https://secwatch.observer/filing/0001708599-25-000105

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer